Lartigau E
Département de radiothérapie, institut Gustave-Roussy, Villejuif, France.
Cancer Radiother. 1998 Dec;2(6):775-80. doi: 10.1016/s1278-3218(99)80022-5.
Hypoxic cells are present in rodent and xenografted human tumours and it has been known for a long time that the absence of oxygen in tumours is a factor of resistance against ionising radiation. The dose modifying role of oxygen (oxygen enhancement ratio) has been largely studied in experimental models. For pO2 values of 2 mmHg, the relative radiosensitivity of tumour cells is intermediate between the maximum sensitivity observed in air and the minimal one observed in hypoxia. The measurement of tumour pO2 in patients (polarographic technique) has demonstrated the presence of low values (< 10 mmHg) in many different tumour sites (ENT, uterine cervix, breast, melanoma, etc). In order to sensitise hypoxic tumours, imidazole have been used in patients, but most of the results were negative. New methods have been developed in the combination of bioreductive drugs of cytotoxic cells to radiotherapy. In this article, we will describe the clinical results obtained in patients with radiosensitising chemical agents.
缺氧细胞存在于啮齿动物肿瘤和异种移植的人类肿瘤中，长期以来人们都知道肿瘤中缺氧是抵抗电离辐射的一个因素。氧的剂量修正作用（氧增强比）已在实验模型中得到大量研究。对于2 mmHg的pO2值，肿瘤细胞的相对放射敏感性介于在空气中观察到的最大敏感性和在缺氧状态下观察到的最小敏感性之间。在患者中测量肿瘤pO2（极谱技术）已证明在许多不同肿瘤部位（耳鼻喉科、子宫颈、乳腺、黑色素瘤等）存在低值（<10 mmHg）。为了使缺氧肿瘤敏感化，咪唑已用于患者，但大多数结果都是阴性的。在将细胞毒性细胞的生物还原药物与放疗相结合方面已开发出新方法。在本文中，我们将描述在使用放射增敏化学剂的患者中获得的临床结果。
